.png){kind=icon}
返回
Improving Immunotherapy Through Glycodesign
.png){kind=icon}
OA
AI
DOI：10.3389/fimmu.2018.02485.png)
.png){kind=icon}
.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Immunotherapy is revolutionizing health care, with the majority of high impact drugs approved in the past decade falling into this category of therapy. Despite considerable success, glycosylation-a key design parameter that ensures safety, optimizes biological response, and influences the pharmacokinetic properties of an immunotherapeutic-has slowed the development of this class of drugs in the past and remains challenging at present. This article describes how optimizing glycosylation through a variety of glycoengineering strategies provides enticing opportunities to not only avoid past pitfalls, but also to substantially improve immunotherapies including antibodies and recombinant proteins, and cell-based therapies. We cover design principles important for early stage pre-clinical development and also discuss how various glycoengineering strategies can augment the biomanufacturing process to ensure the overall effectiveness of immunotherapeutics.
Keyword:
immunotherapy
glycosylation
antibody-drug conjugates (ADCs)
monoclonal antibodies
antibodydependent cell cytotoxicity (ADCC)
glycoengineering
metabolic glycoengineering
AI总结
对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
5.9
论文数:
5.0W
被引数:
22.7W
机构
引用论文
Aberrant Hedgehog Ligands Induce Progressive Pancreatic Fibrosis by Paracrine Activation of Myofibroblasts and Ductular Cells in Transgenic Zebrafish.png)
PLoS ONEOAAI
PLoS ONEIF0
OAAI分享收藏分享收藏
查看更多内容